#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16170	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2109	762.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1435	1435	C	958	C	874	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29416	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3486	840.6	0	.	n	.	0	T695C	SNP	695	695	T	996	996	C	951	C,T	869,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29416	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3486	840.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1638	1638	A	995	A	920	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29416	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3486	840.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2272	2272	C	932	C	850	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29416	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3486	840.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2346	2346	A	949	A,G	889,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29416	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3486	840.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2898	2898	C	911	C,T,A	467,384,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2204	folP	852	852	100.0	folP.l15.c4.ctg.1	1398	156.3	1	SNP	p	R228S	1	.	.	682	684	AGC	976	978	AGC	233;236;238	A;G,A;C	213;213,1;217	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5906	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3358	175.4	1	SNP	p	S91F	0	.	.	271	273	TCC	583	585	TCC	182;181;183	T;C;C	171;170;172	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5906	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3358	175.4	1	SNP	p	D95N	0	.	.	283	285	GAC	595	597	GAC	177;177;178	G;A;C	165;165;167	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5906	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3358	175.4	1	SNP	p	D95G	0	.	.	283	285	GAC	595	597	GAC	177;177;178	G;A;C	165;165;167	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1884	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1420	132.0	0	.	p	.	0	F184L	NONSYN	550	552	TTC	1000	1002	TTG	215;214;217	T;T;G	193;194;194	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1884	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1420	132.0	1	SNP	p	G45D	0	.	.	133	135	GGC	583	585	GGC	233;235;239	G;G;C	220;219;223	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	962	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1182	81.3	0	.	n	.	0	A197.	DEL	197	197	A	645	645	A	226	A	213	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	194.6	1	SNP	p	D86N	0	.	.	256	258	GAC	563	565	GAC	215;216;215	G,A;A;C	200,1;198;201	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	194.6	1	SNP	p	S87W	0	.	.	259	261	AGT	566	568	AGT	218;218;220	A;G,A;T	205;202,1;205	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	194.6	1	SNP	p	S87R	0	.	.	259	261	AGT	566	568	AGT	218;218;220	A;G,A;T	205;202,1;205	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	194.6	1	SNP	p	S87I	0	.	.	259	261	AGT	566	568	AGT	218;218;220	A;G,A;T	205;202,1;205	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	194.6	1	SNP	p	S88P	0	.	.	262	264	TCC	569	571	TCC	217;214;217	T;C;C	204;203;207	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4870	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2566	189.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1524	1526	GGC	205;204;201	G;G;C	187;187;183	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1284	1286	GCA	249;245;246	G;C;A	228;227;227	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1287	1289	ATC	246;250;247	A;T;C	226;228;221	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1299	1301	GTG	244;246;247	G;T;G	221;220;219	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1299	1301	GTG	244;246;247	G;T;G	221;220;219	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1803	1805	ACC	219;219;219	A;C;C,T	194;195;198,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1857	1859	GCG	194;195;196	G;C,T;G	182;164,1;175	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1857	1859	GCG	194;195;196	G;C,T;G	182;164,1;175	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1980	1982	GGC	213;210;206	G;G;C,A	186;183;181,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1989	1991	GGC	195;198;197	G;G;C	168;169;169	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4390	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2325	188.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2007	2009	CCG	174;173;175	C,G;C;G	131,3;132;134	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6344	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3107	203.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1633	1635	CTG	235;231;233	C;T;G	215;211;214	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2716	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1703	158.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	458	458	C	166	C	156	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	269	271	GAA	254;253;252	G;A,C;A	235;231,1;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	680	682	TCA	234;233;239	T;C;A	215;213;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	0	.	p	.	0	E210K	NONSYN	628	630	GAA	785	787	AAA	238;241;243	A;A;A	225;230;229	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	809	811	GTC	239;238;237	G;T;C	222;221;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	821	823	TCT	230;233;236	T;C,G;T	220;222,1;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	1	SNP	p	G120K	1	.	.	358	360	AAG	515	517	AAG	265;266;265	A;A;G	243;245;245	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	1	SNP	p	D121N	0	.	.	361	363	GAC	518	520	GAC	264;264;263	G;A;C	242;242;241	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2960	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1357	213.7	1	SNP	p	A121D	1	.	.	361	363	GAC	518	520	GAC	264;264;263	G;A;C	242;242;241	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10922	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4988	218.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2142	2144	AAT	229;225;224	A;A;T	213;209;208	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1208	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1085	110.7	1	SNP	p	V57M	1	.	.	169	171	ATG	523	525	ATG	254;254;256	A;T;G	235;237;238	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
